Phase 3 investigation of
aprocitentan for resistant
hypertension management
Phase 3 investigation of
clazosentan for patients with
cerebral vasospasm
Phase 3 investigation of
daridorexant for patients with
insomnia
Phase 3 investigation of
lucerastat for patients with
Fabry disease
| Event | When |
| First Quarter 2020 Financial Results reporting* | April 23, 2020 |
| Annual General Meeting of Shareholders | May 13, 2020 |
| Half-Year 2020 Financial Results reporting* | July 23, 2020 |
| Nine-months 2020 Financial Results reporting* | October 22, 2020 |
*We will be in a silent period for 10 days ahead of the financial reporting.
| 02 Apr 2020 | |
| 19 Mar 2020 | |
| 04 Mar 2020 |
Idorsia published its full year financial results 2019 on Thursday February 6, 2020.
Idorsia published its half year financial results 2019 on Tuesday July 23, 2019.
Idorsia published its full year financial results 2018 on Thursday February 7, 2019.
In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.
In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.
In June 2018, Idorsia announced that the first patients had been enrolled in a registration study to investigate the effect of daridorexant (recommended INN for ACT-541468), a dual orexin receptor antagonist, for the treatment of adult and elderly patients with insomnia. NB: The proposed INN "nemorexant" was unsuccessful and will no longer be used in association with ACT-541468.
In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.
The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.